Recce Pharmaceuticals Ltd (ASX:RCE) insider James Graham acquired 650,000 shares of the firm’s stock in a transaction on Wednesday, March 6th. The stock was bought at an average price of A$0.16 ($0.11) per share, with a total value of A$100,750.00 ($71,453.90).

ASX RCE traded up A$0.03 ($0.02) during trading on Thursday, hitting A$0.18 ($0.13). The company had a trading volume of 1,402,727 shares. The company has a quick ratio of 0.08, a current ratio of 0.09 and a debt-to-equity ratio of 0.41. The company has a market cap of $19.28 million and a price-to-earnings ratio of -9.47.

TRADEMARK VIOLATION WARNING: This story was published by Daily Political and is owned by of Daily Political. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at

About Recce Pharmaceuticals

Recce Pharmaceuticals Ltd, a biotechnology company, researches and develops antibiotic drugs in Australia. The company focuses on the development of RECCE 327 that helps to address the problem of antibiotic resistant superbugs. It also develops drugs for the treatment of stomach ulcers and diarrhea. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017.

See Also: How to Profit and Limit Losses With Stop Orders

Receive News & Ratings for Recce Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recce Pharmaceuticals and related companies with's FREE daily email newsletter.